Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

incyte corp. - INCY

INCY

Close Chg Chg %
92.26 -1.96 -2.12%

Closed Market

90.30

-1.96 (2.12%)

Volume: 1.49M

Last Updated:

Mar 27, 2026, 4:00 PM EDT

Trade Now

Company Overview: incyte corp. - INCY

INCY Key Data

Open

$92.28

 Day Range

90.21 - 92.50

52 Week Range

53.56 - 112.29

 Market Cap

$18.36B

Shares Outstanding

199.01M

 Public Float

196.97M

Beta

0.84

 Rev. Per Employee

N/A

P/E Ratio

14.39

 EPS

$6.59

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.68M

  

INCY Performance

1 Week
 
 -0.53%
 
1 Month
 
 -10.83%
 
3 Months
 
 -9.80%
 
1 Year
 
 49.01%
 
5 Years
 
 10.46%
 

INCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About incyte corp. - INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

INCY At a Glance

Incyte Corp.
1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone 1-302-498-6700 Revenue 5.14B
Industry Pharmaceuticals: Major Net Income 1.29B
Sector Health Technology 2025 Sales Growth 21.221%
Fiscal Year-end 12 / 2026 Employees 2,844
View SEC Filings

INCY Valuation

P/E Current 14.391
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 15.407
Price to Sales Ratio 3.856
Price to Book Ratio 3.793
Price to Cash Flow Ratio 14.02
Enterprise Value to EBITDA 11.349
Enterprise Value to Sales 3.17
Total Debt to Enterprise Value 0.003

INCY Efficiency

Revenue/Employee 1,807,750.352
Income Per Employee 452,408.579
Receivables Turnover 5.019
Total Asset Turnover 0.826

INCY Liquidity

Current Ratio 3.316
Quick Ratio 3.249
Cash Ratio 2.363

INCY Profitability

Gross Margin 91.467
Operating Margin 26.117
Pretax Margin 32.374
Net Margin 25.026
Return on Assets 20.664
Return on Equity 29.87
Return on Total Capital 24.637
Return on Invested Capital 29.544

INCY Capital Structure

Total Debt to Total Equity 1.063
Total Debt to Total Capital 1.052
Total Debt to Total Assets 0.788
Long-Term Debt to Equity 0.865
Long-Term Debt to Total Capital 0.856
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Incyte Corp. - INCY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.39B 3.70B 4.24B 5.14B
Sales Growth
+13.67% +8.87% +14.76% +21.22%
Cost of Goods Sold (COGS) incl D&A
253.35M 315.15M 377.72M 438.72M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
67.86M 82.66M 89.25M 93.29M
Depreciation
46.35M 60.16M 65.65M 66.59M
Amortization of Intangibles
21.50M 22.50M 23.60M 26.70M
COGS Growth
+35.24% +24.39% +19.85% +16.15%
Gross Income
3.14B 3.38B 3.86B 4.70B
Gross Income Growth
+12.23% +7.62% +14.29% +21.72%
Gross Profit Margin
+92.54% +91.47% +91.09% +91.47%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.54B 2.73B 3.78B 3.36B
Research & Development
1.59B 1.63B 2.61B 1.98B
Other SG&A
955.78M 1.10B 1.18B 1.38B
SGA Growth
+17.60% +7.36% +38.65% -11.20%
Other Operating Expense
- - - -
-
Unusual Expense
107.71M (12.65M) 18.78M (172.10M)
EBIT after Unusual Expense
491.85M 664.42M 61.37M 1.51B
Non Operating Income/Expense
39.93M 172.35M 257.54M 152.02M
Non-Operating Interest Income
- - 128.71M 105.60M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.67M 2.55M 2.28M 2.43M
Interest Expense Growth
+39.73% -4.31% -10.62% +6.49%
Gross Interest Expense
2.67M 2.55M 2.28M 2.43M
Interest Capitalized
- - - -
-
Pretax Income
529.12M 834.22M 316.63M 1.66B
Pretax Income Growth
-7.24% +57.66% -62.04% +425.68%
Pretax Margin
+15.59% +22.57% +7.47% +32.37%
Income Tax
188.46M 236.62M 284.01M 377.80M
Income Tax - Current - Domestic
128.22M 392.51M 366.64M 123.51M
Income Tax - Current - Foreign
3.14M 3.00M 2.93M 6.61M
Income Tax - Deferred - Domestic
58.40M (159.09M) (84.72M) 247.43M
Income Tax - Deferred - Foreign
(1.31M) 195.00K (828.00K) 252.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
340.66M 597.60M 32.62M 1.29B
Minority Interest Expense
- - - -
-
Net Income
340.66M 597.60M 32.62M 1.29B
Net Income Growth
-64.09% +75.42% -94.54% +3,844.96%
Net Margin Growth
+10.04% +16.17% +0.77% +25.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
340.66M 597.60M 32.62M 1.29B
Preferred Dividends
- - - -
-
Net Income Available to Common
340.66M 597.60M 32.62M 1.29B
EPS (Basic)
1.5345 2.6723 0.1575 6.5913
EPS (Basic) Growth
-64.34% +74.15% -94.11% +4,084.95%
Basic Shares Outstanding
222.00M 223.63M 207.11M 195.20M
EPS (Diluted)
1.5211 2.6451 0.1549 6.4108
EPS (Diluted) Growth
-64.39% +73.89% -94.14% +4,038.67%
Diluted Shares Outstanding
223.96M 225.93M 210.53M 200.70M
EBITDA
667.42M 734.43M 169.39M 1.44B
EBITDA Growth
-4.02% +10.04% -76.94% +747.76%
EBITDA Margin
+19.66% +19.87% +3.99% +27.93%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 109.333
Number of Ratings 28 Current Quarters Estimate 1.398
FY Report Date 03 / 2026 Current Year's Estimate 7.427
Last Quarter’s Earnings 1.80 Median PE on CY Estimate N/A
Year Ago Earnings 6.80 Next Fiscal Year Estimate 8.985
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 20 20 22 21
Mean Estimate 1.40 1.78 7.43 8.98
High Estimates 1.81 2.08 8.43 11.02
Low Estimate 0.81 1.31 6.21 7.95
Coefficient of Variance 19.20 9.20 6.69 9.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 11 11
OVERWEIGHT 1 1 1
HOLD 14 13 13
UNDERWEIGHT 2 1 1
SELL 1 2 2
MEAN Overweight Overweight Overweight

Insider Actions for Incyte Corp. - INCY

Date Name Shares Transaction Value
Feb 24, 2026 Pablo J. Cagnoni President, R&D 253,468 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $61.18 per share 15,507,172.24
Feb 24, 2026 Pablo J. Cagnoni President, R&D 234,800 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $100.91 per share 23,693,668.00
Feb 24, 2026 Pablo J. Cagnoni President, R&D 7,182 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 24, 2026 Pablo J. Cagnoni President, R&D 16,268 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 24, 2026 Pablo J. Cagnoni President, R&D 247,893 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $61.76 per share 15,309,871.68
Jan 22, 2026 Matteo Trotta EVP, GM, Dermatology US 8,542 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Thomas Tray Principal Accounting Officer 2,425 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Lee Heeson EVP, Head of Incyte Intl 38,152 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Michael Morrissey EVP, Head of Tech. Operations 34,250 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $102.62 per share 3,514,735.00
Jan 22, 2026 Michael Morrissey EVP, Head of Tech. Operations 34,679 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Steven H. Stein EVP & Chief Medical Officer 19,932 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Mohamed Khairie Issa EVP, Head of US Oncology 14,237 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 22, 2026 Patrick A Mayes EVP & Chief Scientific Officer 4,218 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Nov 26, 2025 Thomas Tray Principal Accounting Officer 23,573 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103 per share 2,428,019.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 9,438 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 33,200 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.15 per share 2,760,580.00
Sep 19, 2025 Sheila A. Denton EVP & General Counsel 33,478 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $64.25 per share 2,150,961.50
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 9,993 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2025 Vijay Iyengar EVP, GMAPPS 40,540 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.36 per share 2,771,314.40
Jul 18, 2025 Sheila A. Denton EVP & General Counsel 33,200 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.36 per share 2,269,552.00

Incyte Corp. in the News